90 related articles for article (PubMed ID: 20414938)
1. Fibronectin plasma levels in gynecological cancers.
Grammatikakis IE; Botsis DC; Grigoriou OV; Dalamanga AN; Creatsas GC
J BUON; 2010; 15(1):122-6. PubMed ID: 20414938
[TBL] [Abstract][Full Text] [Related]
2. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
3. [Plasmafibronectin in case of tumors of the female genital system].
Tatra G; Nasr F
Strahlentherapie; 1983 Oct; 159(10):606-9. PubMed ID: 6417840
[TBL] [Abstract][Full Text] [Related]
4. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
[TBL] [Abstract][Full Text] [Related]
5. Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy.
von Tempelhoff GF; Nieman F; Heilmann L; Hommel G
Clin Hemorheol Microcirc; 2000; 22(2):107-30. PubMed ID: 10831062
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors].
Peng XP; Li JD; Li MD; Ye XM; Yan WC
Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072
[TBL] [Abstract][Full Text] [Related]
7. [Investigation of serum immunosuppresive acidic protein levels in gynecological tumor].
Zhang W; Wang P; Zhao Y
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):194-6. PubMed ID: 11601039
[TBL] [Abstract][Full Text] [Related]
8. Serum evaluation of P53 protein in patients with gynaecological cancer.
Barbati A; Mariani L; Porpora MG; Anceschi M; Collini P; Lauro V; Cosmi EV
Anticancer Res; 2000; 20(2A):1033-5. PubMed ID: 10810393
[TBL] [Abstract][Full Text] [Related]
9. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
[TBL] [Abstract][Full Text] [Related]
11. Serum prealbumin, transferrin and alpha-1-acid glycoprotein in patients with gynecological carcinomas.
Tosner J; Krejsek J; Louda B
Neoplasma; 1988; 35(4):403-11. PubMed ID: 3141823
[TBL] [Abstract][Full Text] [Related]
12. Knowledge of tumor markers and the psychological consequences of tumor marker sampling in patients with gynecologic cancers.
Mayerhofer K; Bodner K; Aktas C; Schindl M; Kaider A; Leodolter S; Joura EA; Kainz C
Anticancer Res; 2000; 20(2B):1281-4. PubMed ID: 10810435
[TBL] [Abstract][Full Text] [Related]
13. [The plasma level of sL-selectin, myeloperoxidase (MPO) and granulocyte-colony stimulating factor (G-CSF) in gynecological cancer patients].
Czygier M; Ławicki S; Gacuta-Szumarska E; Bedkowska E; Szmitkowski M
Przegl Lek; 2010; 67(3):184-6. PubMed ID: 20687382
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of serum Dkk-3 in patients with gynecological cancer.
Jiang T; Huang L; Wang S; Zhang S
J Obstet Gynaecol Res; 2010 Aug; 36(4):769-73. PubMed ID: 20666943
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
16. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
[TBL] [Abstract][Full Text] [Related]
17. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
Konno R; Takano T; Sato S; Yajima A
Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
[TBL] [Abstract][Full Text] [Related]
18. Plasma fibronectin kinetics during uncomplicated acute myocardial infarction.
Laudat A; Ano-Monfils N; Haddad A; Pileire B
West Indian Med J; 1996 Mar; 45(1):28-30. PubMed ID: 8693735
[TBL] [Abstract][Full Text] [Related]
19. [Constitutive characteristics and change trend of gynecological malignant tumors in 8009 hospitalized patients in Guangxi Zhuang Autonomous Region].
Huang W; Li L; Yu DQ; Huang YL; Liu Y; Chen XQ; Tang BJ; Xu H; Ma G; Dong LH; Li L; Qiu Y; Bai H; Nong WZ; Li L; Zeng DY; Jiang FY; Lan Y; Ye Y; Tang XZ; Wang DX; Li HZ; Pan YB; Mo AX; Wu XY; Lei ZY; Zhou GP; Liu C; Su QH
Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):22-5. PubMed ID: 17331416
[TBL] [Abstract][Full Text] [Related]
20. Prothrombin fragment F1+2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer.
Gadducci A; Marrai R; Baicchi U; Gagetti O; Facchini V; Genazzani AR
Gynecol Oncol; 1996 May; 61(2):215-7. PubMed ID: 8626135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
